How to order from BCCM/ITM | Prices (EUR) excl. VAT | |
Non-Profit | Profit | |
Supply samples from public collection |
10% discount on orders of 10 or more items | |
Biosafety level 1 and 2 strains: freeze dried |
75,00 |
86,00 |
Biosafety level 1 and 2 strains: active(1) |
97,00 |
112,00 |
Biosafety level 1 and 2 strains: thermolysate(1) |
97,00 |
112,00 |
Biosafety level 1 and 2 strains: purified genomic DNA |
124,00 |
139,00 |
Biosafety level 3 strains: freeze dried |
160,00 |
250,00 |
Biosafety level 3 strains: active(1) |
208,00 |
325,00 |
Biosafety level 3 strains: thermolysate(1) |
160,00 |
250,00 |
Biosafety level 3 strains: purified genomic DNA |
235,00 |
352,00 |
BCG clones (from Mycobacterium bovis BCG Pasteur & Danish tn library) (active, thermolysate) |
35,00 |
60,00 |
Public deposit |
||
Deposit of strain in the public collection |
No charges |
No charges |
Safe deposit |
||
Viability and purity check, preservation and the first year of safe-keeping |
||
Biosafety Level 1 and 2 strains |
263,00 |
263,00 |
Biosafety Level 3 strains |
303,00 |
303,00 |
Annual maintenance fee, incl. one yearly viability test, its report, and forwarding the subculture if requested (mailing costs not included) |
|
|
Biosafety Level 1 and 2 strains |
66,00 |
66,00 |
Biosafety Level 3 strains |
76,00 |
76,00 |
Release of a sample(2) |
48,00 |
48,00 |
Preparation of a new batch of samples for long-term storage(3) |
|
|
Biosafety Level 1 and 2 strains |
232,00 |
232,00 |
Biosafety Level 3 strains |
263,00 |
263,00 |
Services(5) |
||
Phenotypic identification |
||
TBD(4) | TBD(4) | |
Genotypic identification by Sanger sequencing |
||
DNA extraction, PCR + Sanger sequencing of 16S rRNA gene and/or rpoB gene |
135, 00 | 135, 00 |
Whole genome sequence analysis species identification |
|
|
gDNA extraction from culture isolate (including required subcultures) |
97,00 | 97,00 |
TBD(6) | TBD(6) | |
WGS analysis |
TBD(6) | TBD(6) |
Phenotypic drug-susceptibility testing for M. tuberculosis complex |
||
Proportion method in MGIT960 system (4 drugs) |
68,00 | 68,00 |
Proportion method on solid medium (6 drugs) |
73,00 | 73,00 |
MIC determination of M. tuberculosis complex |
||
MIC determination on solid medium (1 drug - 6 concentrations) |
81,00 | 81,00 |
MIC determination in MGIT960 system (4 concentrations) |
77,00 | 77,00 |
MIC determination in microtiter plate assay (one plate) |
56,00 | 56,00 |
Spoligotyping for Mycobacterium tuberculosis complex isolates |
43,00 | 43,00 |
Banking fee |
Per invoice | Per invoice |
Shipping fee |
Depending on destination, weight, Biomaterial safety risk level, form of supply | |
Packaging fee |
||
Biosafety Level 1 & 2 materials |
15,00 |
15,00 |
Biosafety Level 3 materials |
35,00 |
35,00 |
(1) Fresh cultures and thermolysates are available upon request.
(2) Only to the depositor or to third parties with the depositor's written authorisation.
(3) A new batch for long term storage is prepared when necessary, for example when the batch is depleted.
(4) As phenotypic identification may cover a broad variety of tests, prices will be discussed case by case
(5) Cost per strain or target includes institutional overhead, but not VAT, and can be negotiated in case of larger numbers to be tested
(6) As WGS analysis is partially outsourced, prices will be discussed case by case
Legal disclaimer
All services are provided exclusively on the basis of the terms and conditions below, regardless of any contradictory conditions stated on the client’s documents.
By having placed an order, the client automatically agreed to these terms and conditions of BCCM/ITM.
BCCM/ITM makes no representation nor warranty, express or implied, to the client with respect to the suitability or fitness of the results for any specific purpose.
In no event shall BCCM/ITM or its staff be liable to the client for any damages or losses.
Under no circumstances shall BCCM/ITM's total liability exceed the total contract value.
These limitations of liability shall not apply in case of willful misconduct or fraud.
The client undertakes to indemnify and hold BCCM/ITM harmless from and against third party claims based on the client’s use or exploitation of the results.